AN2 Therapeutics (ANTX) stock: insider trades, news & valuation
Health Care · Net sellingShare price and insider trades
AN2 Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $12K and 6 sold $398K of ANTX stock on the open market.
Get emailed when insiders cluster-buy stocks like ANTX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ANTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $12K | 1 | $343K | 10 |
| Q2 2026 | — | 0 | $1K | 1 |
| Q1 2026 | — | 0 | $50K | 9 |
| Q4 2025 | — | 0 | $4K | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 AN2 Therapeutics, Inc. insider reported open-market purchases totaling $12K, while 6 insiders reported sales totaling $398K. 8 of 22 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ANTX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 11, 2026 | +20.1% | None | +6.3%S&P -0.1% | -13.9% |
| May 11, 2026 | +4.2% | None | -4.3%S&P +0.1% | +4.2% |
| Mar 17, 2026 | +326.4% | Sold $347 | -1.5%S&P -1.1% | -21.9% |
| Nov 12, 2025 | -11.1% | Sold $4K | -5.8%S&P -1.6% | +6.2% |
| Mar 25, 2025 | +15.3% | None | +0.7%S&P -1.0% | -17.8% |
| Nov 13, 2024 | -3.6% | None | -5.7%S&P -0.6% | +43.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ANTX news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
ANTX stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- 8-K Earnings release
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 11SEC | Robin Shane ReadnourDirector | Sell Plan | 585624,765 held (−0%) | $6.02 | $4K | -26.9% | — |
| Sep 11SEC | Robin Shane ReadnourDirector | Sell Plan | 523557,467 held (−0%) | $6.02 | $3K | -26.9% | — |
| Sep 8SEC | Robin Shane ReadnourDirector | Sell Plan | 5,294625,350 held (−1%) | $6.02 | $32K | -26.9% | — |
| Sep 8SEC | Robin Shane ReadnourDirector | Sell Plan | 4,725557,990 held (−1%) | $6.02 | $28K | -26.9% | — |
| Sep 8SEC | Robin Shane ReadnourDirector | Sell Plan | 3,223630,644 held (−1%) | $6.07 | $20K | -27.5% | — |
| Sep 8SEC | Robin Shane ReadnourDirector | Sell Plan | 2,877562,715 held (−1%) | $6.07 | $17K | -27.5% | — |
| Sep 4SEC | Sarah Joanne WilliamsPrincipal Accounting Officer | Sell | 27266,311 held (−0%) | $5.53 | $2K | -20.4% | — |
| Sep 2SEC | Margaret M FitzpatrickDirector | Buy | 2,09810,708 held (+24%) | $5.53 | $12K | -20.4% | — |
| Aug 19SEC | Robin Shane ReadnourDirector | Sell Plan | 18,706633,867 held (−3%) | $6.01 | $112K | -26.8% | — |
| Aug 19SEC | Robin Shane ReadnourDirector | Sell Plan | 16,696565,592 held (−3%) | $6.01 | $100K | -26.8% | — |
| Jul 10SEC | Joshua M EizenSee Remarks | Sell | 5,945206,554 held (−3%) | $4.17 | $25K | +5.5% | — |
| Jun 2SEC | Sarah Joanne WilliamsPrincipal Accounting Officer | Sell | 26566,583 held (−0%) | $4.43 | $1K | -0.7% | — |
| Mar 5SEC | Sarah Joanne WilliamsPrincipal Accounting Officer | Sell | 32766,848 held (−0%) | $1.06 | $347 | +315.1% | — |
| Jan 7SEC | Joshua M EizenSee Remarks | Sell | 17,923159,430 held (−10%) | $1.00 | $18K | +340.0% | — |
| Jan 7SEC | Joshua M EizenSee Remarks | Sell | 6,931152,499 held (−4%) | $1.01 | $7K | +335.6% | — |
| Jan 7SEC | Sanjay ChandaChief Development Officer | Sell | 5,95675,823 held (−7%) | $1.01 | $6K | +335.6% | — |
| Jan 7SEC | Lucy DayCFO | Sell | 5,51275,363 held (−7%) | $1.01 | $6K | +335.6% | — |
| Jan 7SEC | Stephen David PriorChief Strategy Officer | Sell | 3,60461,944 held (−5%) | $1.00 | $4K | +340.0% | — |
| Jan 7SEC | Lucy DayCFO | Sell | 3,29580,875 held (−4%) | $1.00 | $3K | +340.0% | — |
| Jan 7SEC | Sanjay ChandaChief Development Officer | Sell | 3,29581,779 held (−4%) | $1.00 | $3K | +340.0% | — |
| Jan 7SEC | Stephen David PriorChief Strategy Officer | Sell | 2,85859,086 held (−5%) | $1.01 | $3K | +335.6% | — |
| Nov 6SEC | Joshua M EizenSee Remarks | Sell | 2,819177,353 held (−2%) | $1.14 | $3K | +286.0% | — |
| Nov 6SEC | Stephen David PriorChief Strategy Officer | Sell | 76565,548 held (−1%) | $1.14 | $872 | +286.0% | — |
Insiders at AN2 Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Robin Shane ReadnourDirector | — | $317K | Sep 11, 2026 | — |
| Joshua M EizenSee Remarks | — | $53K | Jul 10, 2026 | — |
| Margaret M FitzpatrickDirector | $12K | — | Sep 2, 2026 | — |
| Sanjay ChandaChief Development Officer | — | $9K | Jan 7, 2026 | — |
| Lucy DayCFO | — | $9K | Jan 7, 2026 | — |
| Stephen David PriorChief Strategy Officer | — | $7K | Jan 7, 2026 | — |
| Sarah Joanne WilliamsPrincipal Accounting Officer | — | $3K | Sep 4, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ANTX stock: common questions
Are AN2 Therapeutics, Inc. insiders buying ANTX stock?
In the past 12 months, 1 insiders reported open-market purchases of ANTX worth $12K. The latest was Director Margaret M Fitzpatrick bought $12K of ANTX at $5.53 — first open-market purchase in our records; raises the stake by 24%.
Are AN2 Therapeutics, Inc. insiders selling ANTX stock?
6 insiders reported sales worth $398K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ANTX's 52-week range?
Over the past year ANTX has traded between $1.03 and $6.28. It last closed at $4.40 on Oct 9, 2026.